Jubilant Pharmova reported total income of INR 1,599.5 crores during the period ended September 30, 2022 as compared to INR 1,657.7 crores during the period ended September 30, 2021 depicting a dip of 3% while the net profit further plummeted by 97% as the company posted net profit INR 5 crores for the period ended September 30, 2022 vs INR 142 crores during the same period ended September 30, 2021.
Similarly, the EPS also dipped by 96% as it reported EPS of INR 0.34. This vast dip was due to CDMO – Sterile Injectables and Generics as the segment was impacted by the pricing pressure in the US market and challenges related to import.